Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Revance Therapeutics, Inc. - Common Stock (NQ:RVNC)

3.650 UNCHANGED
Last Price Updated: 4:00 PM EST, Feb 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Revance Therapeutics, Inc. - Common Stock

< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
46 Biggest Movers From Yesterday
Gainers Valneva SE (NASDAQ: VALN) shares surged 39.8% to close at $39.21 on Monday after the company reported VLA2001 met both co-primary endpoints in the Phase 3 pivotal trial... 
Via Benzinga
Lost Money in Revance Therapeutics, Inc.?
From Gibbs Law Group
Via Business Wire
REVANCE THERAPEUTICS INVESTOR ALERT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures Product Safety
Mid-Afternoon Market Update: Dow Falls 70 Points; Evolving Systems Shares Spike Higher
Toward the end of trading Monday, the Dow traded down 0.20% to 35,223.86 while the NASDAQ rose 0.68% to 14,998.54. The S&P also rose, gaining 0.19% to 4,480.05. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Progenity (NASDAQ:PROG) shares increased by 33.17% to $2.85 during Monday's regular session. As of 12:30 EST, Progenity's stock is trading at a volume of... 
Via Benzinga
Revance Stock Loses 40% Of Its Value After FDA Rejects Its Frown Lines Injection
Revance Therapeutics tumbled Monday after the FDA rejected its frown lines injection. 
Via Investor's Business Daily
Exposures Product Safety
Mid-Day Market Update: Nasdaq Rises 50 Points; Revance Therapeutics Shares Plummet
Midway through trading Monday, the Dow traded down 0.05% to 35,275.96 while the NASDAQ rose 0.34% to 14,948.46. The S&P also rose, gaining 0.19% to 4,479.71. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures US Equities
34 Stocks Moving In Monday's Mid-Day Session
Gainers Valneva SE (NASDAQ: VALN) shares jumped 34.6% to $37.75 after the company reported VLA2001 met both co-primary endpoints in the Phase 3 pivotal trial Cov-Compare.... 
Via Benzinga
Mid-Morning Market Update: Markets Mostly Lower; Albertsons Tops Q2 Estimates
Following the market opening Monday, the Dow traded down 0.32% to 35,182.99 while the NASDAQ rose 0.12% to 14,915.84. The S&P also fell, dropping 0.06% to 4,468.81. The U.S.... 
Via Benzinga
Topics Stocks
Exposures US Equities
These 2 Nasdaq Biotechs Are Making Huge Premarket Moves Monday
The Nasdaq looks poised to open slightly lower after a strong week. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
10 Biggest Price Target Changes For Monday
Barclays reduced the price target for The Walt Disney Company (NYSE: 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Valneva (NASDAQ:VALN) stock increased by 35.65% to $38.05 during Monday's pre-market session. The market value of their outstanding shares is at $1.8 billion.... 
Via Benzinga
Why Revance Therapeutics Stock Is Getting Crushed Today
A surprise rejection is weighing on the biopharma's shares today. 
Via The Motley Fool
21 Stocks Moving in Monday's Pre-Market Session
Gainers Valneva SE (NASDAQ: VALN) rose 34.4% to $37.69 in pre-market trading after the company disclosed positive Phase 3 results for inactivated, adjuvanted COVID-19 vaccine... 
Via Benzinga
Exposures COVID-19
Revance Shares Plunge On FDA Response Letter For Frown Line Candidate
The FDA has issued a Complete Response Letter (CRL) regarding Revance Therapeutics Inc's (NASDAQ: RVNC) marketing application for DaxibotulinumtoxinA for... 
Via Benzinga
Exposures Product Safety
REVANCE ALERT: Bragar Eagel & Squire, P.C. is Investigating Revance Therapeutics, Inc. on Behalf of Revance Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Revance Provides Regulatory Update on DaxibotulinumtoxinA for Injection for the Treatment of Moderate to Severe Glabellar (Frown) Lines
From Revance Therapeutics, Inc.
Via Business Wire
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Revance Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Revance Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
RVNC BREAKING NEWS: ROSEN, A TOP RANKED LAW FIRM, Encourages Revance Therapeutics, Inc. Investors with Losses to Inquire About Class Action Investigation – RVNC
From Rosen Law Firm
Via Business Wire
50 Biggest Movers From Yesterday
Gainers Jasper Therapeutics, Inc. (NASDAQ: JSPR) shares surged 105.1% to close at $14.79 on Wednesday after Oppenheimer initiated coverage on the stock with an Outperform rating... 
Via Benzinga
40 Stocks Moving In Wednesday's Mid-Day Session
Gainers Jasper Therapeutics, Inc. (NASDAQ: JSPR) shares jumped 113% to $15.36 after Oppenheimer initiated coverage on the stock with an Outperform rating and a $21 price target... 
Via Benzinga
Why Revance Therapeutics Stock Is Bolting Higher Today
Management's response to a publicly disclosed regulatory form has investors doing a U-turn. 
Via The Motley Fool
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Revance Therapeutics (NASDAQ:RVNC) stock moved upwards by 17.79% to $24.09 during Wednesday's pre-market session. The company's market cap stands at $1.7... 
Via Benzinga
10 Biggest Price Target Changes For Wednesday
MKM Partners raised the price target on Continental Resources, Inc. (NYSE: 
Via Benzinga
The Daily Biotech Pulse: FDA Nod For Lilly, Regulus Slumps On Study Discontinuation, ObSeva Strikes Linzagolix Commercialization Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Revance Clarifies Gabellar Line Treatment Review On Track Responding to the... 
Via Benzinga
Exposures Product Safety
45 Biggest Movers From Yesterday
Gainers ESSTech Inc (NYSE: GWH) shares surged 128.4% to close at $23.80 onTuesday. ESS Inc, the Bill Gates-backed battery maker went public on the NewYork Stock Exchange on... 
Via Benzinga
Revance Continues to Anticipate FDA Approval of DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines in 2021
From Revance Therapeutics, Inc.
Via Business Wire
Revance Announces the Launch of OPUL™, the First-of-its-Kind Relational Commerce Platform for Aesthetic Practices
From Revance Therapeutics, Inc.
Via Business Wire
Revance to Showcase Data from Phase 3 ASPEN-1 Clinical Trial Evaluating Efficacy, Duration of Effect and Safety of DaxibotulinumtoxinA for Injection for Cervical Dystonia at International Parkinson and Movement Disorder Society Virtual Congress 2021
From Revance Therapeutics, Inc.
Via Business Wire
< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.